Ruthenium(II)-catalyzed asymmetric transfer hydrogenation for enantioselective synthesis of (S)-/(R)-4-ethyl-N-[(2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]benzamide exhibiting differing antinociceptive effects
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2026.109491 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Sudhakar Dattatray Tanpure und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, ROC. Hauptthemen laut MEDLINE: Analgesics, Benzamides, Ruthenium. Die Arbeit nennt 37 Literaturangaben. Gefördert von: National Tsing Hua University, Taiwan Ministry of Science and Technology, National Health Research Institutes.
Abstract (Originalsprache)
In this study, we developed a modified asymmetric transfer hydrogenation (ATH) methodology to reduce 2-[(3,4-dihydroisoquinolin-1-yl)methyl]isoindoline-1,3-diones, yielding both S- and R-enantiomers with excellent enantioselectivities. Chiral ligands (S,S)-TIPSDPEN and (R,R)-TIPSDPEN were employed to generate ruthenium complexes with [RuCl₂(C₆H₆)]₂, thereby establishing efficient reduction conditions. Subsequently, we synthesized both enantiomers of compound 44 from our previous study using the developed ATH method and evaluated their in vitro μ-opioid receptor agonist activity, as well as their in vivo antinociceptive effects, and gastrointestinal transit inhibition side effects. Our findings highlight that each enantiomer exhibits distinct interactions with its target receptor, resulting in different pharmacological profiles. Notably, (S)-4-ethyl-N-[(2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]benzamide [(+)-(S)-5a] demonstrated superior antinociceptive activity and reduced constipation and hERG channel inhibition compared to its (-)-(R)-5a enantiomer and the racemic mixture, indicating promising potential for drug development. These results confirm that chirality plays a pivotal role in determining pharmacological activity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, ROC.
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, ROC; Ph.D. Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Med…
- Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli County 35053, Taiwan, ROC; School of Pharmacy, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan,…
Förderung
- National Tsing Hua University
- Taiwan Ministry of Science and Technology
- National Health Research Institutes
- National Yang Ming Chiao Tung University
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Tanpure, S. D., Chang, Y. C., Chang, H. F., Yeh, S. H., & Ueng, S. H. (2026). Ruthenium(II)-catalyzed asymmetric transfer hydrogenation for enantioselective synthesis of (S)-/(R)-4-ethyl-N-[(2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]benzamide exhibiting differing antinociceptive effects. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2026.109491
Vancouver
Tanpure SD, Chang YC, Chang HF, Yeh SH, Ueng SH. Ruthenium(II)-catalyzed asymmetric transfer hydrogenation for enantioselective synthesis of (S)-/(R)-4-ethyl-N-[(2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]benzamide exhibiting differing antinociceptive effects. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2026.109491
BibTeX
@article{Tanpure2026,
author = {Tanpure, Sudhakar Dattatray and Chang, Yung-Chiao and Chang, Hsiao-Fu and Yeh, Shiu-Hwa and Ueng, Shau-Hua},
title = {Ruthenium(II)-catalyzed asymmetric transfer hydrogenation for enantioselective synthesis of (S)-/(R)-4-ethyl-N-[(2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]benzamide exhibiting differing antinociceptive effects},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2026.109491}
}
EUVIMED